Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Close up of hand pipetting in lab

Through the collaboration, Oxford academics, including Kennedy Investigators Profs. Fiona Powrie and Christopher Buckley, and Dr Brian Marsden, will work with Janssen scientists to develop a cellular map of genes and proteins implicated across a range of immune-mediated inflammatory disorders and characterise pharmacologically relevant therapeutic targets. The agreement was facilitated by Johnson & Johnson Innovation.

Lead Oxford investigator for the project, Professor Holm Uhlig (Nuffield Department of Medicine) said, “This exciting endeavour brings together a world leading group of Janssen and Oxford scientists to form the Cartography collaboration. This project aims to create a detailed cellular map across multiple immune disorders which has the potential to advance the understanding of disease mechanisms, how to treat the right patients with the right medications, and the development of new therapies.”

Speaking of the partnership, Professor Fiona Powrie said, “The Oxford/Janssen collaboration is an extremely exciting initiative. It offers a unique opportunity to define the cellular basis of disease, to identify shared and unique processes across different inflammatory diseases informing the development of personalised medicine approaches.”

Immune mediated inflammatory disorders affect a large proportion of the population. Genetic association studies, functional studies, and clinical observations suggest that there is substantial overlap between immune mediated inflammatory disorders affecting different organ systems, but the cellular mechanisms are largely unknown.

This 3-year data-driven study, will apply the latest molecular and cellular multiomics analysis platforms, and computational methods to deliver insights for target selection and precision medicine for inflammatory disease indications of the intestine, the joint and the skin where existing options for therapeutic intervention are limited. The collaboration will create four new postdoctoral positions at the University of Oxford. 

Similar stories

£1.2M to improve diagnosis of emergency spinal condition

The National Institute for Health and Care Research has awarded an Advanced Fellowship to Dr David Metcalfe to study the diagnosis of the spinal condition, cauda equina syndrome.

Professor Chris Lavy appointed to WHO technical advisory group

Congratulations to Professor Chris Lavy, who has been appointed to the World Health Organization’s (WHO) technical advisory group for integrated clinical care for a period of two years.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.

Gene variant links trigger finger and carpal tunnel syndrome

A new NDORMS study, published in The Lancet Rheumatology, has found a genetic variant that increases the risk of both carpal tunnel syndrome and trigger finger, and opens the door for new therapies that involve blocking the IGF-1 pathway.

Kennedy programmes support early career researchers

Since 2013 the Kennedy Institute of Rheumatology has been running a Career Development Programme, a scheme to help early career researchers launch their own independent laboratories, and more recently the Innovator Investigator Programme to bring new technologies to core research themes.

OCTRU collaboration boosts understanding of COVID vaccine response

Working with researchers across multiple universities, the Oxford Clinical Trials Unit (OCTRU) played a key role in delivering results of the national VROOM trial (Vaccine Response On Off Methotrexate).